Kyverna Therapeutics Inc (KYTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 131,618 | 224,287 | 34,647 | 0 | 0 |
| Marketable Securities | 214,619 | 145,507 | 22,896 | 0 | 0 |
| TOTAL | $348,823 | $375,488 | $60,664 | $0 | $0 |
| Non-Current Assets | |||||
| PPE Net | 3,366 | 2,714 | 2,326 | N/A | N/A |
| Other Non-Current Assets | 10,927 | 11,782 | 12,205 | 0 | 0 |
| TOTAL | $14,293 | $14,496 | $14,531 | $N/A | $N/A |
| Total Assets | $363,116 | $389,984 | $75,195 | $0 | $0 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 4,861 | 7,451 | 4,358 | 0 | 0 |
| Accrued Expenses | 8,972 | 7,613 | 9,062 | 0 | 0 |
| Other current liabilities | N/A | 3,083 | N/A | 0 | 0 |
| TOTAL | $23,478 | $21,865 | $19,859 | $0 | $0 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 5,722 | 6,461 | 185,812 | 0 | 0 |
| TOTAL | $6,129 | $7,128 | $186,733 | $N/A | $N/A |
| Total Liabilities | $29,607 | $28,993 | $206,592 | $0 | $0 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 43,147 | 43,115 | N/A | N/A | N/A |
| Retained earnings | -191,539 | -162,736 | -136,043 | 0 | 0 |
| Other shareholders' equity | -37 | -1 | 4 | 0 | 0 |
| TOTAL | $333,509 | $360,991 | $-131,397 | $0 | $0 |
| Total Liabilities And Equity | $363,116 | $389,984 | $75,195 | $0 | $0 |